astodrimer

dendrimer-based microbicide gel

Also Known As:

BRI-7013; BRI-7013 sodium; BRI7013; N2,N6-bis(N2,N6-bis(N2,N6-bis(N2,N6-bis(N2,N6-bis((3,6- disulfonaphthalen-1-yloxy)acetyl)-L-lysyl)-L-lysyl)-L-lysyl)-L-lysyl)- N1-(diphenylmethyl)-L-lysinamide; NIH compound 6436; SPL 7013; SPL-7013; SPL-7013 sodium; SPL7013; StarPharmaLTD 7013; VivaGel; astodrimer sodium; tetrahexacontasodium N2,N6-bis(N2,N6-bis(N2,N6-bis(N2,N6-bis(N2,N6-bis((3,6- disulfonaphthalen-1-yloxy)acetyl)-L-lysyl)-L-lysyl)-L-lysyl)-L-lysyl)- N1-(diphenylmethyl)-L-lysinamide

Networked: 21 relevant articles (4 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Paull, Jeremy R A: 10 articles (01/2022 - 07/2005)
2.	Castellarnau, Alex: 6 articles (01/2022 - 01/2020)
3.	Heery, Graham P: 4 articles (01/2022 - 01/2021)
4.	Kinghorn, George R: 4 articles (01/2022 - 01/2020)
5.	McCloud, Philip: 4 articles (01/2022 - 01/2020)
6.	Price, Clare F: 4 articles (04/2021 - 01/2011)
7.	Luscombe, Carolyn A: 3 articles (01/2022 - 01/2021)
8.	Schwebke, Jane R: 3 articles (04/2021 - 01/2020)
9.	Waldbaum, Arthur S: 3 articles (04/2021 - 01/2020)
10.	Cummins, James E: 3 articles (05/2008 - 11/2005)

Related Diseases

1.	Bacterial Vaginosis 07/01/2021 - "Astodrimer gel is effective in treating bacterial vaginosis and corroborated by clinical (Amsel criteria) and microbiological (Nugent score) measurements as well as patient-reported symptoms. " 02/01/2020 - "These results support a role for Astodrimer 1 % Gel as an effective, safe and well-tolerated treatment for women with bacterial vaginosis." 01/01/2020 - "These results support a role for Astodrimer Gel, 1%, as an effective treatment for bacterial vaginosis." 07/01/2021 - "We attempted to conduct a systematic review and meta-analysis of all randomized controlled trials (RCTs) which examined the efficacy and safety of astodrimer gel in patients with bacterial vaginosis. " 07/01/2021 - "Astodrimer gel for treatment of bacterial vaginosis: A systematic review and meta-analysis of randomized controlled trials."
2.	Infections 01/01/2021 - "Astodrimer sodium 1% resulted in a significant reduction of viral genome copies in nasal secretions vs. PBS on Day 7 post-infection. " 12/01/2003 - "From these studies a lead compound and formulation (2V of SPL7013) was chosen for ongoing evaluations in primate models of simian immunodeficiency virus and Chlamydia trachomatis infection." 01/01/2021 - "Astodrimer sodium also inhibited infection in a primary human airway epithelial cell line. " 06/01/2011 - "In addition, the mode of action by which SPL7013 prevents infection of cells with X4 and R5X4 strains is likely to differ from R5 strains of HIV-1." 05/01/2006 - "However, a single intravaginal application of the 3% (wt/wt) SPL7013 gel did not provide protection from the acquisition of cervical chlamydial infection."
3.	Vulvovaginal Candidiasis 02/01/2020 - "For the combined studies, adverse events potentially related to treatment occurred in 14.7 % (37/252) of astodrimer patients vs 9.4 % (23/244) for placebo, including vulvovaginal candidiasis reported for 2.4 % (6/252) of astodrimer patients. " 07/01/2021 - "Moreover, astodrimer gel is largely safe and associated with marginal rate of vulvovaginal candidiasis." 07/01/2021 - "With respect to safety outcomes (n = 614 astodrimer gel versus n = 551 placebo), astodrimer gel demonstrated equal tolerability to placebo for all pooled safety endpoints, expect unfavourably for vulvovaginal candidiasis and treatment-related vulvovaginal candidiasis. " 04/01/2021 - "Vulvovaginal candidiasis and urinary tract infection occurred more often in women receiving astodrimer. "
4.	Herpes Simplex 05/15/2011 - "The study was designed to assess the safety, adherence, acceptability, and effect on vaginal microflora of 3% SPL7013 Gel (VivaGel), a novel dendrimer topical microbicide that inhibits HIV, herpes simplex virus-2, and human papillomavirus in vitro and in animal models. "
5.	Vaginal Discharge 02/01/2020 - "A greater proportion of women receiving astodrimer reported absence of vaginal discharge and absence of vaginal odor at day 9-12 and day 21-30 compared with placebo. " 01/01/2020 - "A greater proportion of patients reported absence of vaginal discharge and vaginal odor at day 9-12 and day 21-30 for Astodrimer Gel groups compared with placebo. " 04/01/2021 - "A significantly lower proportion of patients receiving astodrimer compared with placebo had recurrence of bacterial vaginosis at or by Week 16 by other secondary measures, including individual Amsel criteria (vaginal discharge and clue cells) and Nugent score 7-10. "

Related Drugs and Biologics

1.	astodrimer
2.	Anti-Infective Agents (Microbicides)
3.	Dendrimers (Dendrons)
4.	PRO 2000 (PRO-2000)
5.	Antiviral Agents (Antivirals)
6.	Nasal Sprays
7.	Nonoxynol (Nonoxynol 9)
8.	Vaginal Creams, Foams, and Jellies (Vaginal Tablet)
9.	Cellulose
10.	UC-781

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Intravaginal Administration
4.	Intranasal Administration